178 related articles for article (PubMed ID: 36774237)
41. Emerging therapeutic targets for neurofibromatosis type 1.
Walker JA; Upadhyaya M
Expert Opin Ther Targets; 2018 May; 22(5):419-437. PubMed ID: 29667529
[TBL] [Abstract][Full Text] [Related]
42. Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning.
Anastasaki C; Woo AS; Messiaen LM; Gutmann DH
Hum Mol Genet; 2015 Jun; 24(12):3518-28. PubMed ID: 25788518
[TBL] [Abstract][Full Text] [Related]
43. Physical interaction between neurofibromin and serotonin 5-HT6 receptor promotes receptor constitutive activity.
Deraredj Nadim W; Chaumont-Dubel S; Madouri F; Cobret L; De Tauzia ML; Zajdel P; Bénédetti H; Marin P; Morisset-Lopez S
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12310-12315. PubMed ID: 27791021
[TBL] [Abstract][Full Text] [Related]
44. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
Brems H; Legius E
Keio J Med; 2013; 62(4):107-12. PubMed ID: 24334617
[TBL] [Abstract][Full Text] [Related]
45. [Pathogenic alterations within the neurofibromin gene in various cancers].
Nagy Á; Garzuly F; Kálmán B
Magy Onkol; 2017 Dec; 61(4):327-336. PubMed ID: 29257151
[TBL] [Abstract][Full Text] [Related]
46. Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction.
Xu J; Ismat FA; Wang T; Lu MM; Antonucci N; Epstein JA
Circ Res; 2009 Jul; 105(3):304-11. PubMed ID: 19574548
[TBL] [Abstract][Full Text] [Related]
47. Tranilast inhibits the expression of genes related to epithelial-mesenchymal transition and angiogenesis in neurofibromin-deficient cells.
Harigai R; Sakai S; Nobusue H; Hirose C; Sampetrean O; Minami N; Hata Y; Kasama T; Hirose T; Takenouchi T; Kosaki K; Kishi K; Saya H; Arima Y
Sci Rep; 2018 Apr; 8(1):6069. PubMed ID: 29666462
[TBL] [Abstract][Full Text] [Related]
48. Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome.
Thiel C; Wilken M; Zenker M; Sticht H; Fahsold R; Gusek-Schneider GC; Rauch A
Am J Med Genet A; 2009 Jun; 149A(6):1263-7. PubMed ID: 19449407
[TBL] [Abstract][Full Text] [Related]
49. Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.
Le LQ; Shipman T; Burns DK; Parada LF
Cell Stem Cell; 2009 May; 4(5):453-63. PubMed ID: 19427294
[TBL] [Abstract][Full Text] [Related]
50. Malignant Peripheral Nerve Sheath Tumor in an Army Reservist With Neurofibromatosis Type 1.
Kou CJ; Rendo M; Broadwater DR; Beeler B
Mil Med; 2021 May; 186(5-6):e626-e631. PubMed ID: 33180928
[TBL] [Abstract][Full Text] [Related]
51. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A
J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256
[TBL] [Abstract][Full Text] [Related]
52. NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response.
Xu J; Ismat FA; Wang T; Yang J; Epstein JA
Circulation; 2007 Nov; 116(19):2148-56. PubMed ID: 17967772
[TBL] [Abstract][Full Text] [Related]
53. Pigment cell-related manifestations in neurofibromatosis type 1: an overview.
De Schepper S; Boucneau J; Lambert J; Messiaen L; Naeyaert JM
Pigment Cell Res; 2005 Feb; 18(1):13-24. PubMed ID: 15649148
[TBL] [Abstract][Full Text] [Related]
54. The NF1 gene revisited - from bench to bedside.
Yap YS; McPherson JR; Ong CK; Rozen SG; Teh BT; Lee AS; Callen DF
Oncotarget; 2014 Aug; 5(15):5873-92. PubMed ID: 25026295
[TBL] [Abstract][Full Text] [Related]
55. Neurofibromin (NF1) genetic variant structure-function analyses using a full-length mouse cDNA.
Wallis D; Li K; Lui H; Hu K; Chen MJ; Li J; Kang J; Das S; Korf BR; Kesterson RA
Hum Mutat; 2018 Jun; 39(6):816-821. PubMed ID: 29522274
[TBL] [Abstract][Full Text] [Related]
56. Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras.
Yunoue S; Tokuo H; Fukunaga K; Feng L; Ozawa T; Nishi T; Kikuchi A; Hattori S; Kuratsu J; Saya H; Araki N
J Biol Chem; 2003 Jul; 278(29):26958-69. PubMed ID: 12730209
[TBL] [Abstract][Full Text] [Related]
57. Identification of a Novel
Xu G; Li M; Niu Y; Huang X; Li Y; Tang G; Long S; Zhao H; Jiang H
Biomed Res Int; 2019; 2019():2721357. PubMed ID: 31886188
[TBL] [Abstract][Full Text] [Related]
58. Neurofibromatosis type 1: pathology, clinical features and molecular genetics.
von Deimling A; Krone W; Menon AG
Brain Pathol; 1995 Apr; 5(2):153-62. PubMed ID: 7670656
[TBL] [Abstract][Full Text] [Related]
59. Neurofibromatosis type 1: piecing the puzzle together.
Feldkamp MM; Gutmann DH; Guha A
Can J Neurol Sci; 1998 Aug; 25(3):181-91. PubMed ID: 9706718
[TBL] [Abstract][Full Text] [Related]
60. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
